Abstract YO3
Case summary
METASTATIC BREAST CANCER TO ESOPHAGUS: A CASE REPORT AND REVIEW OF THE LITERATURE
Secondary esophageal carcinoma from a breast primary is an infrequent phenomenon occurring in around 0.4% of patients. It is pertinent to rule out esophageal metastasis when a patient of breast carcinoma present with dysphagia after a long DFS. Most esophageal metastasis are usually submucosal deposition, requiring EUS-FNB for diagnosis. Given the rarity of this presentation and failure of diagnosis by simple mucosal biopsy during patient’s lifetime, there is a general lack of consensus on management guidelines in these patients.
Herein we report a case of 65 year old female presented with dysphagia who was subsequently diagnosed with esophageal metastases, 14years post surgery for breast cancer. She was treated with a combination of systemic Chemotherapy, hormonal therapy and local radiotherapy comprising both external beam radiotherapy(EBRT) and Intraluminal radiotherapy(ILRT). We also performed a comprehensive review of literature on esophageal metastases from breast primary, aiming to improve the diagnostic accuracy and treatment efficacy in this rare presentation. Our patient tolerated the treatment well and achieved a significant symptomatic improvement post Radiotherapy. Reviewing various literature, we observed 83% patients presented with complaints of dysphagia after a median of 13 years post breast surgery, with 72% metastases involving mid thoracic esophagus while majority were hormonally receptive.
We conclude that patients presenting with dysphagia post breast cancer treatment, should undergo EUS-FNB to rule out esophageal metastasis. While surgical interventions were effective treatment in some cases, we suggest systemic Chemotherapy with Hormonal therapy, and radiotherapy for local control as the management of choice in these patients. Even though prognosis is difficult to predict , this combined modality of treatment seems to achieve a better overall survival.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
399P - Role of denosumab as targeted therapy in treatment of unresectable or recurrent cases of giant cell tumor of the bone
Presenter: Anchal Mishra
Session: Poster viewing 06
400P - Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
Presenter: Omid Hamid
Session: Poster viewing 06
401P - A phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors
Presenter: Shunsuke Kondo
Session: Poster viewing 06
402P - Phase I study of selumetinib in Chinese pediatric and adult patients (pts) with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): Interim results
Presenter: Xiao-Jun Yuan
Session: Poster viewing 06
403P - Gender trend over time of principal investigators within large Australian cancer clinical trials groups
Presenter: Thi Thao Vi Luong
Session: Poster viewing 06
404P - Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India
Presenter: Vishwapriya Godkhindi
Session: Poster viewing 06
405P - Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019
Presenter: Ross Soo
Session: Poster viewing 06
406P - Adrenal insufficiency induced by immune checkpoint inhibitors: Clinical characteristics of 145 cases
Presenter: kaoru koshiba
Session: Poster viewing 06
407P - A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan
Presenter: Naoya Yamazaki
Session: Poster viewing 06
408P - Machine learning for glioblastoma screening from histopathology whole slide imaging
Presenter: Eva Yi Wah Cheung
Session: Poster viewing 06